Answers are grounded in this paper and cite their sources.
BACKGROUND: The R21/Matrix-M (R21) malaria vaccine candidate, recommended by WHO for use in young children, could be extended to the whole population. Seasonal mass vaccination (SMV) before peak malaria transmission could be a promising tool to accelerate progress towards malaria elimination. We aimed to evaluate the safety and effectiveness of SMV with R21 in two malaria-endemic settings in west Africa. METHODS: This open-label, cluster-randomised, controlled trial was conducted in The Gambia, a setting with low-to-moderate seasonal transmission, and Burkina Faso, a setting with intense seasonal transmission. 54 medium-sized villages (30 in The Gambia and 24 in Burkina Faso) were randomly assigned (1:1) by use of computer-restricted randomisation to receive either SMV with R21 (intervention group) or no SMV (control group). All study villages received national standard malaria control interventions. In the intervention group, residents who were aged 5 months and older, willing to comply with trial procedures, and could provide written informed consent (from parents or guardians for children aged <18 years plus assent for children aged 12-17 years) were eligible for vaccination. The intervention was delivered as three monthly doses of 5 μg (participants aged <15 years) or 10 μg (participants aged ≥15 years) R21 plus 50 μg of Matrix-M. The primary outcome was malaria prevalence at peak transmission, defined as the proportion of participants with Plasmodium falciparum infection assessed by quantitative PCR. This trial is registered with ClinicalTrials.gov (NCT06578572) and the Pan-African Clinical Trials Registry (PACTR202404544467702), and is ongoing. FINDINGS: The intervention was delivered between May 30, and Aug 21, 2024. A cross-sectional survey to estimate the primary endpoint was conducted between Nov 18 and Dec 6, 2024. The population available for vaccination varied across the three rounds. In The Gambia, among 4311 total residents in intervention villages, 2565 (59·5%) received three vaccine doses; in Burkina Faso, among 6235 total residents in intervention villages, 4072 (65·3%) received three vaccine doses. SMV with R21 reduced the odds of malaria infection by 70% (adjusted odds ratio 0·30 [95% CI 0·20-0·44]; p<0·0001) in The Gambia and by 25% (0·75 [95% CI 0·58-0·98]; p=0·036) in Burkina Faso. In The Gambia, prevalence decreased across all age groups, whereas in Burkina Faso the largest effect was observed in children younger than 5 years. The vaccine was safe and well tolerated. 651 adverse events were reported in 581 (13·5%) vaccine recipients in The Gambia, and 795 adverse events were reported in 705 (11·3%) vaccine recipients in Burkina Faso. Among 69 serious adverse events reported overall, only one was considered related to vaccination (febrile convulsions in a female participant aged 8 years after the second dose in The Gambia). INTERPRETATION: SMV with R21 reduced malaria prevalence in both settings. It could become an additional strategy for malaria control in endemic areas of seasonal transmission. In low-to-moderate transmission settings, the vaccine could accelerate progress towards elimination; in high-transmission areas it could further reduce the malaria burden.
No takes yet. Share an insight, caveat, or question.
Dabira et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: